FindTrial
Sign In

Dose of Teicoplanin for injection and clinical outcomes, safety and pharmacoeconomics: a retrospective study

Dose of Teicoplanin for injection and clinical outcomes, safety and pharmacoeconomics: a retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033521
Enrollment
Unknown
Registered
2020-06-03
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Disease

Interventions

case series:Nil

Sponsors

Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients admitted to Nanjing Gulou Hospital for treatment from January 1, 2019 to December 31, 2019; 2. Patients treated with teicoplanin.

Exclusion criteria

Exclusion criteria: 1. Cases diagnosed in hospital or not infected during the period of admission; 2. Patients who used teicoplanin less than 48 hours; 3. Cases of simultaneous use of vancomycin; 4. In the process of using the computer EMR system to obtain data, there is a lack of items and incomplete data.

Design outcomes

Primary

MeasureTime frame
Clinical Outcome;medication safety (liver injury, kidney injury, ototoxicity, allergic reaction);—

Secondary

MeasureTime frame
Clinical efficacy;—

Countries

China

Contacts

Public ContactDayu Chen

Nanjing Drum Tower Hospital

1044548733@qq.com+86 15951916689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026